Phosphatidylinositol 3-Kinases
"Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
| Descriptor ID |
D019869
|
| MeSH Number(s) |
D08.811.913.696.620.500
|
| Concept/Terms |
Phosphatidylinositol 3-Kinases- Phosphatidylinositol 3-Kinases
- Phosphatidylinositol 3 Kinases
- Phosphoinositide 3-Hydroxykinase
- PI 3-Kinase
- PtdIns 3-Kinases
- 3-Kinases, PtdIns
- PtdIns 3 Kinases
- PI-3K
- PI3 Kinases
- Kinases, PI3
- PI3-Kinase
- PtdIns 3-Kinase
- Phosphatidylinositol-3-OH Kinase
- PI-3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 18 | 20 |
| 1996 | 0 | 13 | 13 |
| 1997 | 1 | 13 | 14 |
| 1998 | 17 | 8 | 25 |
| 1999 | 19 | 18 | 37 |
| 2000 | 20 | 18 | 38 |
| 2001 | 19 | 26 | 45 |
| 2002 | 34 | 36 | 70 |
| 2003 | 24 | 45 | 69 |
| 2004 | 34 | 44 | 78 |
| 2005 | 30 | 49 | 79 |
| 2006 | 25 | 42 | 67 |
| 2007 | 34 | 52 | 86 |
| 2008 | 30 | 47 | 77 |
| 2009 | 37 | 43 | 80 |
| 2010 | 24 | 47 | 71 |
| 2011 | 17 | 51 | 68 |
| 2012 | 23 | 54 | 77 |
| 2013 | 28 | 48 | 76 |
| 2014 | 23 | 40 | 63 |
| 2015 | 22 | 49 | 71 |
| 2016 | 16 | 52 | 68 |
| 2017 | 14 | 26 | 40 |
| 2018 | 10 | 24 | 34 |
| 2019 | 12 | 24 | 36 |
| 2020 | 13 | 17 | 30 |
| 2021 | 4 | 22 | 26 |
| 2022 | 8 | 45 | 53 |
| 2023 | 8 | 35 | 43 |
| 2024 | 3 | 19 | 22 |
Below are the most recent publications written about "Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment. Nat Commun. 2024 Nov 23; 15(1):10164.
-
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
-
Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review. Med Oncol. 2024 Aug 09; 41(9):222.
-
Sphingosine 1-Phosphate Stimulates ER to Golgi Ceramide Traffic to Promote Survival in T98G Glioma Cells. Int J Mol Sci. 2024 Jul 29; 25(15).
-
Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. Anticancer Res. 2024 Jul; 44(7):2787-2792.
-
PTP1B phosphatase dampens iPSC-derived neutrophil motility and antimicrobial function. J Leukoc Biol. 2024 Jun 28; 116(1):118-131.
-
A high dose KRP203 induces cytoplasmic vacuoles associated with altered phosphoinositide segregation and endosome expansion. Biochem Biophys Res Commun. 2024 07 23; 718:149981.
-
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proc Natl Acad Sci U S A. 2024 Apr 23; 121(17):e2321898121.
-
Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma. Mod Pathol. 2024 Jun; 37(6):100488.
-
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 03 26; 8(6):1515-1528.